LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.
P/B ratio for LumiraDx Limited (LMDX)
P/B ratio as of 2022: -2.27
According to LumiraDx Limited's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -2.27. At the end of 2021 the company had a P/B ratio of 8.91.
P/B ratio history for LumiraDx Limited from 2019 to 2022
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2022 | -2.27 |
| 2021 | 8.91 |
| 2020 | -6.60 |
| 2019 | -16.22 |